Background
==========

Sjögren's syndrome is a tissue-specific autoimmune disease that affects exocrine tissues, especially salivary glands and lacrimal glands. It is one of the most common autoimmune disorders in the U.S., with an estimated prevalence of 2--4 million people. The autoimmune-mediated damage of the salivary and lacrimal glands in Sjögren's syndrome leads to a decrease in the production of saliva and tears and to the development of dry mouth and dry eyes. Without the lubricating and protective functions of saliva and tears, the oral and ocular surfaces are subject to infections and discomfort, leading to a significantly reduced quality of life \[[@B1],[@B2]\].

Development of Sjögren's syndrome requires a complex interplay between a number of genetic, hormonal and environmental factors, most of which have not been defined. Genetic linkages, especially involving major histocompatibility complex (MHC) genes, have been reported for Sjögren's syndrome but it is not clear if, or how, the associated genes are involved in the development of the disease \[[@B3]\]. Additional non-MHC genes have also been linked with the development of Sjögren's syndrome.

In addition to genetic predisposition, some studies suggest that infection of a genetically-susceptible individual by a virus or other pathogen might trigger the development of an autoimmune disease \[[@B4]\]. The proposed mechanisms include activation of the innate immune system, release of self antigens from damaged or apoptotic tissues, and molecular mimicry that results in activation of T cells and/or B cells that react with tissue antigens \[[@B4]\].

Both the innate and the adaptive immune systems are involved in the pathogenesis of Sjögren's syndrome. The type I interferon (IFN) pathway, which plays an important role in the innate immune response to viruses, is also thought to play an important role in the development of Sjögren's syndrome and other autoimmune disorders, including SLE \[[@B5],[@B6]\]. Moreover, type I IFNs can activate the adaptive immune system directly, by binding to IFN receptors on antigen presenting cells, T cells and B cells, or indirectly, by inducing the production and release of cytokines and chemokines that bind to these cells.

Autoantibodies to intracellular antigens, notably the nuclear proteins SSA/Ro and SSB/La, are found in the sera of many patients with Sjögren's syndrome. These autoantibodies are thought to develop when intracellular antigens, some of which have undergone proteolytic cleavage that reveals new antigenic epitopes, become "visible" to the immune system in membrane blebs on the surface of apoptotic cells \[[@B7]\]. Alternatively, antigenic epitopes from bacteria and viruses, including Epstein-Barr virus (EBV) and coxsackie virus, may act as molecular mimics that trigger the development of antibodies that cross react with similar epitopes on target tissue autoantigens \[[@B2],[@B8],[@B9]\]. Although autoantibodies to intracellular antigens are useful in the diagnosis of Sjögren's syndrome, it is not clear if they play a direct role in the development of salivary gland and lacrimal gland damage and hypofunction. In contrast, autoantibodies to the M3 muscarinic acetylcholine receptor (M3R) have been directly implicated in salivary gland hypofunction in the nonobese diabetic (NOD) mouse model of Sjögren's syndrome \[[@B10]\]. Importantly, function-inhibiting anti-M3R autoantibodies are found in the sera of many patients with Sjögren's syndrome \[[@B11]\].

Current therapy for Sjögren's syndrome usually consists of palliative treatment that relieves the symptoms of dry eye and dry mouth, but fails to modify the underlying disease. Novel disease-modifying treatment strategies, based on recent immunological insights in Sjögren\'s syndrome and other autoimmune diseases, have met with mixed results \[[@B12]\]. For example, in recent clinical trials, treatment of Sjögren\'s syndrome patients with a B cell-depleting anti-CD20 monoclonal antibody (rituximab) led to significant improvement of the stimulated whole saliva flow rate and a reduction in parotid gland inflammation \[[@B13]\]. In contrast, TNFα inhibitors have been ineffective in the treatment of Sjögren\'s syndrome. Detailed studies on the immune response in Sjögren's syndrome patients treated with one of the inhibitors (etanercept) revealed an increase in the circulating levels of TNFα \[[@B14]\]. These results suggest that TNFα may not play a pivotal role in the disease and that other therapeutic targets must be identified.

Despite a large body of evidence gathered over the past 60 years, significant gaps still exist in our understanding of Sjögren's syndrome. Recent gene expression and proteomic studies have identified many genes and pathways that may play a role in the pathogenesis of Sjögren's syndrome \[[@B15]-[@B17]\]. However, validation of these data will require significant additional effort. As an initial step in this validation, we have compiled the published data on Sjögren's syndrome that is not derived from gene expression or proteomic studies. No such unifying database currently exists. Through data curation, the existing data have been uniformly formatted to allow systematic retrieval and comparisons to newly generated gene expression data. As an example of its functionality, the Sjögren\'s Syndrome Knowledge Base (SSKB) was analyzed for biological functions and pathways that are likely to play a role in the disease.

Construction and content
========================

Data mining
-----------

To catalog the existing knowledge in the field, we used text mining to generate the Sjögren's Syndrome Knowledge Base (SSKB) of published gene/protein data ( <http://sskb.umn.edu/>) \[[@B18]\]. The focus of this data-base is on individually identified genes and proteins. Thus, microarray experiments were not included. The raw data for SSKB was extracted from PubMed \[[@B19]\]) using the text mining program EBIMed ( <http://www.ebi.ac.uk/Rebholz-srv/ebimed/>) \[[@B20]\] with the search term \"Sjogren\'s Syndrome\" restricted to \"MeshHeadingsList\". The foundational search identified over 7,700 abstracts and approximately 500 potential genes/proteins. The SSKB is continually updated by regular automated searches of PubMed followed by manual curation.

Curation of raw data
--------------------

The identified abstracts were manually evaluated to remove duplicates and false-positives. In older publications, where gene names were not readily identifiable, names were assigned based on in depth evaluation of the protein name context and available gene data in public databases, including the National Center for Biotechnology Information's Entrez search engine \[[@B21]\] and UniProt \[[@B22],[@B23]\]. The SSKB includes data from human studies and animal models. For the genes identified in animal models, the human homolog was identified by automated ortholog search, using WebGestalt 2.0 \[[@B24],[@B25]\]. These steps reduced the database to 477 current entries. The online database contains the fully curated data and currently contains 413 entries, which can be accessed at <http://sskb.umn.edu>. Updates and newly curated data are continually added.

The 477 entries were sorted to identify autoantigens and viral/bacterial antigens, resulting in 377 potential functional genes, which were used for enrichment and pathway analysis.

Enrichment analysis
-------------------

The 377 human gene entries were used for subsequent enrichment analyses in Webgestalt \[[@B24],[@B25]\]. Gene enrichment in the SSKB gene set was compared to the human genome using the hypergeometric test with multiple test adjustment \[[@B26]\] and a significance level of P \<0.01.

The Gene Ontology \[[@B27],[@B28]\] was accessed with Webgestalt and analysis was restricted to processes and functions represented by two or more genes. Pathway analysis was performed with Webgestalt in the Kyoto Encyclopedia of Genes and Genomes (KEGG) \[[@B29],[@B30]\]. The selection was restricted to pathways with 4 or more genes represented, resulting in identification of 72 KEGG pathways. The "salivary secretion" pathway (KO04970) was recently added to KEGG (11/9/10) and was not included in this analysis. This pathway contains 59 genes, seven of which are found in the SSKB gene set.

Utility and discussion
======================

We constructed a database containing proteins and genes associated with Sjögren's syndrome in human disease or animal models, as identified by text mining of published data. The public SSKB currently contains 413 genes/proteins and can be viewed online ( <http://sskb.umn.edu/>). All genes have been assigned gene symbols and UniProt IDs, which allows rapid retrieval of gene-specific data from external databases. The SSKB data base can be used to determine whether a list of genes is enriched with known Sjögren's syndrome genes and one can carry out a function enrichment analysis (hypergeometric distribution). Individual genes and the corresponding gene products, synonyms and alternate names can be searched by using a web browser search function. Autoantigens, viral antigens and bacterial antigens are separately identified under "Antigens". The SSKB is continually maintained and updated and new genes are added as their analysis is completed.

Based on the abstracts used to retrieve the SSKB genes/proteins, 85 proteins were initially characterized as autoantigens and 15 proteins were characterized as viral (14) or bacterial (1) antigens. Not surprisingly, SSA/Ro and SSB/La were among the most frequently retrieved autoantigens. It has been proposed that viral or bacterial antigens act as autoimmune triggers by molecular mimicry of endogenous human proteins \[[@B2],[@B8],[@B9]\]. However, eight of the 14 putative viral antigens in SSKB were selected for BLAST analysis, which did not identify strong sequence similarity with human proteins (not shown).

The 377 proteins not identified as autoantigens or microbial antigens were considered candidates for functional genes that could play a role in the initiation and progression of Sjögren's syndrome. Since the gene list contains data from humans and animals, the corresponding human genes were identified, with the assumption that genes identified in animal models of Sjögren's syndrome may also be involved in the human disease.

Gene ontology
-------------

The Gene Ontology database \[[@B27]\] was queried to identify the biological processes, cellular components and molecular functions associated with genes in the SSKB (Table [1](#T1){ref-type="table"}). The 40 most highly enriched entries were identified in each category.

###### 

Gene Ontology enrichment analysis

  **Rank**   **BIOLOGICAL PROCESS**                                                                                                      **GO ID**    **Reference Genes**   **Observed Genes**   **Ratio**
  ---------- --------------------------------------------------------------------------------------------------------------------------- ------------ --------------------- -------------------- -----------
  1          regulation of lymphocyte proliferation                                                                                      GO:0050670   81                    32                   39.51%
  2          regulation of leukocyte proliferation                                                                                       GO:0070663   82                    32                   39.02%
  3          regulation of mononuclear cell proliferation                                                                                GO:0032944   82                    32                   39.02%
  4          adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains   GO:0002460   112                   38                   33.93%
  5          adaptive immune response                                                                                                    GO:0002250   113                   38                   33.63%
  6          lymphocyte proliferation                                                                                                    GO:0046651   112                   37                   33.04%
  7          leukocyte proliferation                                                                                                     GO:0070661   114                   37                   32.46%
  8          mononuclear cell proliferation                                                                                              GO:0032943   114                   37                   32.46%
  9          regulation of lymphocyte activation                                                                                         GO:0051249   141                   42                   29.79%
  10         regulation of cell activation                                                                                               GO:0050865   168                   46                   27.38%
  11         regulation of leukocyte activation                                                                                          GO:0002694   159                   43                   27.04%
  12         positive regulation of immune system process                                                                                GO:0002684   229                   60                   26.20%
  13         regulation of immune response                                                                                               GO:0050776   218                   54                   24.77%
  14         immune effector process                                                                                                     GO:0002252   200                   45                   22.50%
  15         regulation of immune system process                                                                                         GO:0002682   362                   79                   21.82%
  16         lymphocyte activation                                                                                                       GO:0046649   272                   59                   21.69%
  17         leukocyte activation                                                                                                        GO:0045321   324                   66                   20.37%
  18         inflammatory response                                                                                                       GO:0006954   359                   71                   19.78%
  19         cell activation                                                                                                             GO:0001775   366                   71                   19.40%
  20         immune response                                                                                                             GO:0006955   750                   133                  17.73%
  21         regulation of response to stimulus                                                                                          GO:0048583   441                   75                   17.01%
  22         defense response                                                                                                            GO:0006952   657                   100                  15.22%
  23         immune system process                                                                                                       GO:0002376   1066                  162                  15.20%
  24         response to wounding                                                                                                        GO:0009611   560                   85                   15.18%
  25         response to external stimulus                                                                                               GO:0009605   904                   110                  12.17%
  26         multi-organism process                                                                                                      GO:0051704   668                   79                   11.83%
  27         regulation of programmed cell death                                                                                         GO:0043067   812                   92                   11.33%
  28         regulation of apoptosis                                                                                                     GO:0042981   805                   91                   11.30%
  29         regulation of cell death                                                                                                    GO:0010941   815                   92                   11.29%
  30         regulation of cell proliferation                                                                                            GO:0042127   739                   79                   10.69%
  31         apoptosis                                                                                                                   GO:0006915   1063                  102                  9.60%
  32         programmed cell death                                                                                                       GO:0012501   1071                  102                  9.52%
  33         response to chemical stimulus                                                                                               GO:0042221   1243                  117                  9.41%
  34         cell proliferation                                                                                                          GO:0008283   1056                  98                   9.28%
  35         death                                                                                                                       GO:0016265   1171                  107                  9.14%
  36         cell death                                                                                                                  GO:0008219   1167                  106                  9.08%
  37         response to stress                                                                                                          GO:0006950   1696                  144                  8.49%
  38         positive regulation of biological process                                                                                   GO:0048518   1865                  153                  8.20%
  39         positive regulation of cellular process                                                                                     GO:0048522   1699                  130                  7.65%
  40         response to stimulus                                                                                                        GO:0050896   3471                  221                  6.37%
  **Rank**   **CELLULAR COMPONENT**                                                                                                      **GO ID**    **Count**             **Observed**         **Ratio**
  1          calcineurin complex                                                                                                         GO:0005955   5                     3                    60.00%
  2          external side of plasma membrane                                                                                            GO:0009897   131                   40                   30.53%
  3          platelet alpha granule lumen                                                                                                GO:0031093   41                    12                   29.27%
  4          MHC class II protein complex                                                                                                GO:0042613   14                    4                    28.57%
  5          nerve terminal                                                                                                              GO:0043679   14                    4                    28.57%
  6          cytoplasmic membrane-bounded vesicle lumen                                                                                  GO:0060205   44                    12                   27.27%
  7          vesicle lumen                                                                                                               GO:0031983   46                    12                   26.09%
  8          integrin complex                                                                                                            GO:0008305   29                    7                    24.14%
  9          platelet alpha granule                                                                                                      GO:0031091   52                    12                   23.08%
  10         high-density lipoprotein particle                                                                                           GO:0034364   24                    5                    20.83%
  11         MHC protein complex                                                                                                         GO:0042611   38                    7                    18.42%
  12         plasma lipoprotein particle                                                                                                 GO:0034358   34                    6                    17.65%
  13         protein-lipid complex                                                                                                       GO:0032994   34                    6                    17.65%
  14         cell surface                                                                                                                GO:0009986   305                   51                   16.72%
  15         axon part                                                                                                                   GO:0033267   48                    7                    14.58%
  16         extracellular space                                                                                                         GO:0005615   670                   84                   12.54%
  17         receptor complex                                                                                                            GO:0043235   113                   13                   11.50%
  18         secretory granule                                                                                                           GO:0030141   174                   19                   10.92%
  19         membrane raft                                                                                                               GO:0045121   131                   14                   10.69%
  20         extracellular region part                                                                                                   GO:0044421   939                   94                   10.01%
  21         axon                                                                                                                        GO:0030424   148                   14                   9.46%
  22         cell soma                                                                                                                   GO:0043025   155                   13                   8.39%
  23         soluble fraction                                                                                                            GO:0005625   297                   24                   8.08%
  24         cytoplasmic vesicle part                                                                                                    GO:0044433   177                   13                   7.34%
  25         extracellular region                                                                                                        GO:0005576   1984                  143                  7.21%
  26         basolateral plasma membrane                                                                                                 GO:0016323   190                   13                   6.84%
  27         lysosome                                                                                                                    GO:0005764   206                   14                   6.80%
  28         integral to plasma membrane                                                                                                 GO:0005887   1183                  72                   6.09%
  29         intrinsic to plasma membrane                                                                                                GO:0031226   1206                  73                   6.05%
  30         cytoplasmic membrane-bounded vesicle                                                                                        GO:0016023   537                   32                   5.96%
  31         membrane-bounded vesicle                                                                                                    GO:0031988   555                   32                   5.77%
  32         extracellular matrix                                                                                                        GO:0031012   335                   19                   5.67%
  33         neuron projection                                                                                                           GO:0043005   318                   18                   5.66%
  34         plasma membrane part                                                                                                        GO:0044459   1918                  104                  5.42%
  35         cell fraction                                                                                                               GO:0000267   1039                  55                   5.29%
  36         cytoplasmic vesicle                                                                                                         GO:0031410   628                   33                   5.25%
  37         vesicle                                                                                                                     GO:0031982   655                   33                   5.04%
  38         insoluble fraction                                                                                                          GO:0005626   803                   34                   4.23%
  39         plasma membrane                                                                                                             GO:0005886   3650                  139                  3.81%
  40         cytosol                                                                                                                     GO:0005829   1251                  47                   3.76%
  **Rank**   **MOLECULAR FUNCTION**                                                                                                      **GO ID**    **COUNT**             **Observed**         **RATIO**
  1          arginine binding                                                                                                            GO:0034618   3                     3                    100.00%
  2          nitric-oxide synthase activity                                                                                              GO:0004517   3                     3                    100.00%
  3          tetrahydrobiopterin binding                                                                                                 GO:0034617   3                     3                    100.00%
  4          C-X-C chemokine binding                                                                                                     GO:0019958   8                     4                    50.00%
  5          beta-amyloid binding                                                                                                        GO:0001540   13                    5                    38.46%
  6          tumor necrosis factor receptor binding                                                                                      GO:0005164   21                    8                    38.10%
  7          chemokine activity                                                                                                          GO:0008009   47                    17                   36.17%
  8          chemokine receptor binding                                                                                                  GO:0042379   49                    17                   34.69%
  9          coreceptor activity                                                                                                         GO:0015026   19                    6                    31.58%
  10         tumor necrosis factor receptor superfamily binding                                                                          GO:0032813   31                    9                    29.03%
  11         cytokine receptor binding                                                                                                   GO:0005126   178                   46                   25.84%
  12         chemokine binding                                                                                                           GO:0019956   26                    6                    23.08%
  13         cytokine activity                                                                                                           GO:0005125   196                   45                   22.96%
  14         growth factor receptor binding                                                                                              GO:0070851   67                    14                   20.90%
  15         collagen binding                                                                                                            GO:0005518   35                    7                    20.00%
  16         G-protein-coupled receptor binding                                                                                          GO:0001664   107                   20                   18.69%
  17         integrin binding                                                                                                            GO:0005178   58                    9                    15.52%
  18         cysteine-type endopeptidase activity                                                                                        GO:0004197   71                    10                   14.08%
  19         growth factor activity                                                                                                      GO:0008083   161                   19                   11.80%
  20         cytokine binding                                                                                                            GO:0019955   108                   12                   11.11%
  21         protein heterodimerization activity                                                                                         GO:0046982   189                   21                   11.11%
  22         glycosaminoglycan binding                                                                                                   GO:0005539   139                   14                   10.07%
  23         protein complex binding                                                                                                     GO:0032403   196                   19                   9.69%
  24         receptor binding                                                                                                            GO:0005102   856                   83                   9.70%
  25         receptor signaling protein activity                                                                                         GO:0005057   159                   15                   9.43%
  26         pattern binding                                                                                                             GO:0001871   153                   14                   9.15%
  27         peptidase inhibitor activity                                                                                                GO:0030414   154                   14                   9.09%
  28         carbohydrate binding                                                                                                        GO:0030246   349                   29                   8.31%
  29         endopeptidase activity                                                                                                      GO:0004175   370                   28                   7.57%
  30         polysaccharide binding                                                                                                      GO:0030247   153                   14                   9.15%
  31         protein dimerization activity                                                                                               GO:0046983   514                   36                   7.00%
  32         identical protein binding                                                                                                   GO:0042802   618                   38                   6.15%
  33         enzyme binding                                                                                                              GO:0019899   505                   29                   5.74%
  34         peptidase activity                                                                                                          GO:0008233   563                   30                   5.33%
  35         peptidase activity, acting on L-amino acid peptides                                                                         GO:0070011   546                   29                   5.31%
  36         molecular transducer activity                                                                                               GO:0060089   2116                  98                   4.63%
  37         signal transducer activity                                                                                                  GO:0004871   2116                  98                   4.63%
  38         receptor activity                                                                                                           GO:0004872   1674                  71                   4.24%
  39         protein binding                                                                                                             GO:0005515   8041                  280                  3.48%
  40         binding                                                                                                                     GO:0005488   12465                 320                  2.57%

The table ranks the gene enrichment in *biological processes*, *cellular component* and *molecular function* with corresponding GO IDs. For each GO ID, the number of *Observed Genes* identified in the SSKB was divided by the number of *Reference Genes* in the human genome to calculate the Ratio of enrichment (Ratio).

The most highly enriched *biological processes* (19 of 40; 18 of the top 20) were associated with immune function, including leukocyte proliferation, leukocyte activation, and regulation of the immune response. Other prominent biological processes were associated with apoptosis and cell death. Thus, the SSKB data set is consistent with recent microarray data \[[@B16]\] and reflects current models for the biological processes involved in the pathogenesis of Sjögren\'s syndrome \[[@B5],[@B31],[@B32]\].

The most highly enriched *cellular component* was the calcineurin complex, which plays a major role in the activation of T cells. Interestingly, in placebo-controlled clinical trials, treatment of Sjögren's syndrome patients with eye drops that contain the calcineurin inhibitor cyclosporine, led to significant improvement in several of the signs and symptoms of dry eye \[[@B33]\].

Other highly enriched *cellular components* include: 1) platelet alpha granules. Although platelet activation has been reported in the salivary glands of Sjögren\'s syndrome patients \[[@B34]\], a direct search of PubMed for "platelet alpha granules" with "sjogren's" did not retrieve any published studies. Thus, while the proteins identified were retrieved from the literature, their potential association with platelet alpha granules in Sjögren's syndrome has not previously been noted. 2) MHC protein complexes were identified and are presumably involved in the presentation of autoantigens \[[@B16]\]. 3) The finding that protein-lipid complexes and lipoprotein particles are associated with Sjögren\'s syndrome may be consistent with changes in serum lipid levels in Sjögren\'s syndrome patients \[[@B35]\] although the prevalence of anti-phospholipid antibodies is low in Sjögren\'s syndrome \[[@B36]\]. 4) Nerve terminals and axons were also prominent cellular components, consistent with the known neurological component of Sjögren\'s syndrome \[[@B37]\].

In *molecular function*, nitric oxide synthase (NOS) activity was the most highly enriched, although only three genes (NOS1-3) were identified. Nitric oxide (NO) signaling appears to be directly affected in salivary and lacrimal glands in Sjögren's syndrome \[[@B38]\]. Other highly enriched molecular functions include chemokine and cytokine activity/receptor binding (8 of the top 15) and peptidase activities.

Pathway analysis
----------------

The SSKB gene list was submitted to KEGG \[[@B29]\] to identify biological pathways potentially associated with Sjögren's syndrome. A total of 72 KEGG pathways showed highly significant enrichment (P \<0.001) in this analysis (Table [2](#T2){ref-type="table"}).

###### 

Biological pathways associated with SSKB genes

  **Rank**   **PATHWAY**                                                  **SSKB Genes**   **ENRICHMENT**   **Raw P**   **Adjust P**
  ---------- ------------------------------------------------------------ ---------------- ---------------- ----------- --------------
  1          Allograft rejection                                          23               76.02            3.62E-39    6.82E-38
  2          Intestinal immune network for IgA production                 27               67.82            7.26E-44    2.05E-42
  3          Asthma                                                       14               58.61            4.14E-22    2.75E-21
  4          Type I diabetes mellitus                                     20               57.09            9.13E-31    9.38E-30
  5          Graft-versus-host disease                                    18               53.83            3.21E-27    2.79E-26
  6          Autoimmune thyroid disease                                   22               52.13            1.29E-32    1.82E-31
  7          Primary immunodeficiency                                     14               50.24            6.38E-21    3.79E-20
  8          Hematopoietic cell lineage                                   33               47.1             1.39E-46    5.24E-45
  9          Toll-like receptor signaling pathway                         37               46.01            1.13E-51    6.38E-50
  10         Apoptosis                                                    25               35.68            5.55E-32    6.97E-31
  11         NOD-like receptor signaling pathway                          17               34.44            7.61E-22    4.78E-21
  12         Amyotrophic lateral sclerosis (ALS)                          14               33.18            5.81E-18    2.85E-17
  13         Other glycan degradation                                     4                31.4             6.67E-06    1.24E-05
  14         Cytokine-cytokine receptor interaction                       66               31.05            5.91E-79    6.68E-77
  15         T cell receptor signaling pathway                            26               30.24            4.12E-31    4.66E-30
  16         RIG-I-like receptor signaling pathway                        17               30.07            9.98E-21    5.64E-20
  17         Cell adhesion molecules (CAMs)                               32               29.99            6.40E-38    1.03E-36
  18         Bladder cancer                                               10               29.9             1.06E-12    3.24E-12
  19         Viral myocarditis                                            17               29.25            1.68E-20    9.04E-20
  20         Cytosolic DNA-sensing pathway                                13               29.16            5.78E-16    2.42E-15
  21         Pancreatic cancer                                            15               26.17            1.88E-17    8.50E-17
  22         Small cell lung cancer                                       16               23.92            7.32E-18    3.45E-17
  23         Glycosaminoglycan degradation                                4                23.92            2.13E-05    3.65E-05
  24         Natural killer cell mediated cytotoxicity                    25               22.92            1.06E-26    8.56E-26
  25         ErbB signaling pathway                                       13               22.16            2.51E-13    8.86E-13
  26         Epithelial cell signaling in Helicobacter pylori infection   12               22.16            2.64E-13    9.04E-13
  27         Complement and coagulation cascades                          12               21.84            3.17E-13    1.05E-12
  28         B cell receptor signaling pathway                            13               21.77            3.38E-14    1.23E-13
  29         Prion diseases                                               6                21.53            3.27E-07    6.84E-07
  30         Antigen processing and presentation                          15               21.17            5.49E-16    2.39E-15
  31         Colorectal cancer                                            14               20.93            6.14E-15    2.48E-14
  32         Adipocytokine signaling pathway                              11               20.62            6.05E-12    1.80E-11
  33         Chemokine signaling pathway                                  30               19.83            7.80E-30    7.35E-29
  34         Prostate cancer                                              14               19.76            1.42E-14    5.53E-14
  35         Glioma                                                       10               19.32            1.10E-10    2.89E-10
  36         Jak-STAT signaling pathway                                   23               18.64            1.67E-22    1.18E-21
  37         Non-small cell lung cancer                                   8                18.61            1.13E-08    2.50E-08
  38         Melanoma                                                     10               17.69            2.71E-10    6.96E-10
  39         Pathways in cancer                                           46               17.51            9.85E-43    2.23E-41
  40         Fc epsilon RI signaling pathway                              11               17.49            3.90E-11    1.05E-10
  41         Chronic myeloid leukemia                                     10               16.75            4.74E-10    1.19E-09
  42         GnRH signaling pathway                                       12               14.92            3.42E-11    9.43E-11
  43         Leukocyte transendothelial migration                         14               14.9             7.91E-13    2.48E-12
  44         VEGF signaling pathway                                       9                14.87            1.04E-08    2.35E-08
  45         Hypertrophic cardiomyopathy (HCM)                            10               14.78            1.67E-09    4.10E-09
  46         p53 signaling pathway                                        8                14.56            8.19E-08    1.75E-07
  47         Endometrial cancer                                           6                14.49            3.65E-06    7.11E-06
  48         Systemic lupus erythematosus                                 16               14.35            3.27E-14    1.23E-13
  49         MAPK signaling pathway                                       30               14.01            3.15E-25    2.37E-24
  50         Focal adhesion                                               22               13.75            1.21E-18    6.21E-18
  51         Dilated cardiomyopathy                                       10               13.65            3.66E-09    8.44E-09
  52         Type II diabetes mellitus                                    5                13.36            3.63E-05    6.12E-05
  53         Neurotrophin signaling pathway                               13               12.96            3.17E-11    8.96E-11
  54         ECM-receptor interaction                                     8                11.96            3.85E-07    7.91E-07
  55         Alzheimer\'s disease                                         16               11.89            6.32E-13    2.04E-12
  56         Lysosome                                                     11               11.81            2.86E-09    6.73E-09
  57         Arginine and proline metabolism                              5                11.63            7.15E-05    0.0001
  58         Renal cell carcinoma                                         6                10.77            2.09E-05    3.63E-05
  59         Long-term depression                                         6                10.77            2.09E-05    3.63E-05
  60         Long-term potentiation                                       6                10.77            2.09E-05    3.63E-05
  61         Proteasome                                                   4                10.47            0.0006      0.0009
  62         Progesterone-mediated oocyte maturation                      7                10.22            6.00E-06    1.15E-05
  63         TGF-beta signaling pathway                                   7                10.11            6.48E-06    1.22E-05
  64         Regulation of actin cytoskeleton                             16               9.3              2.69E-11    7.79E-11
  65         Calcium signaling pathway                                    13               9.17             2.36E-09    5.67E-09
  66         Wnt signaling pathway                                        11               9.15             4.17E-08    9.06E-08
  67         Gap junction                                                 6                8.37             8.67E-05    0.0001
  68         Cell cycle                                                   8                7.85             9.32E-06    1.70E-05
  69         Oocyte meiosis                                               7                7.71             3.80E-05    6.31E-05
  70         Axon guidance                                                7                6.82             8.33E-05    0.0001
  71         Endocytosis                                                  10               6.72             2.93E-06    5.81E-06
  72         Metabolic pathways                                           26               2.96             1.12E-06    2.26E-06

The table lists the number of *SSKB genes* associated with individual KEGG pathways. The pathways are ranked according to their *Enrichment* relative to the number of reference genes in the human genome based on the hypergeometric test. The *raw P*-values (hypergeometric test) and the multiple test-*adjusted P*-values are listed for each pathway.

The pathway analysis revealed dominant pathways associated with immune regulation. Indeed, the eight most highly enriched pathways were associated with antigen presenting cells and activation of T cells and B cells.

Several cancer associated pathways were identified. This is partly due to the overlap between cancer pathways. These pathways typically include cytokine or growth factor stimulation of cell cycle and cell death and were not further analyzed.

Pathways associated with apoptosis, cytokine signaling and inflammation were also highly enriched. To focus on the events associated with initiation of Sjögren\'s syndrome, we analyzed pathways with known triggers. Several of the highly enriched pathways are triggered by bacterial toxins, viral DNA, or viral RNA. These include signaling pathways for Toll-like receptor, NOD-like receptor, RIG-I-like receptor signaling pathways and the cytosolic DNA-sensing pathway.

Overlap with other autoimmune diseases
--------------------------------------

The KEGG pathways include several pathways for autoimmune diseases, including type I diabetes mellitus, autoimmune thyroid disease, and SLE. While about 50% of the genes associated with the first two pathways are also associated with Sjögren\'s syndrome, only 16 Sjögren\'s syndrome genes were identified in the 140-gene SLE pathway (KEGG ID: hsa05322). These findings suggest that significant differences exist in the pathogenesis of autoimmune diseases.

Conclusions
===========

The results of this analysis can serve as a background and comparison for the increasing number of gene expression data sets available for Sjögren's syndrome, e.g. \[[@B15]-[@B17]\]. Preliminary analysis of such data sets suggest that the biological pathways identified in the SSKB are very similar to those identified in human parotid tissue but quite different from those identified in human labial salivary glands \[[@B15]\]. Future analyses will further define these differences and focus on the comparison of biological pathways identified in human tissues and mouse models of Sjögren's syndrome. It is envisioned that the SSKB data can also serve as the starting point for literature reviews and literature-based validation of identified genes; functional gene enrichment studies; protein-protein interaction networks and other bioinformatics analyses; it can be used to arrive at gene sets for SNP set enrichment analysis (pathway based GWAS studies); it can be used to define a gene set for gene set enrichment analysis (GSEA); as a starting point for bioinformatics analysis protein-protein interaction networks (based on yeast 2 hybrid) can be identified among the SSKB genes.
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